Treatment of dyspeptic symptoms with YamatoGast. A non-interventional study of a registered traditional herbal Rikkunshito extract product from Japanese Kampo Medicine in routine practice in Germany.
| Autor: | Reißenweber-Hewel H; Outpatient Clinic for Internal Medicine, Gastroenterology and Japanese Medicine, Gräfelfing/München, Germany., Pehl C; Medizinische Klinik, Krankenhaus Vilsbiburg, Vilsbiburg, Germany., Cameron S; Department for Gastroenterology and Internal Medicine, Klinikum Hann. Münden, Hann. Münden, Germany.; Department of Gastroenterology and GI-Oncology, University Medical Center Göttingen, Göttingen, Germany., Thomsen J; G. Pohl-Boskamp GmbH und Co KG, Hohenlockstedt, Germany., Röschmann-Doose K; G. Pohl-Boskamp GmbH und Co KG, Hohenlockstedt, Germany. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Zeitschrift fur Gastroenterologie [Z Gastroenterol] 2024 Jun; Vol. 62 (6), pp. 909-918. Date of Electronic Publication: 2023 Oct 05. |
| DOI: | 10.1055/a-2164-4534 |
| Abstrakt: | Introduction: Dyspeptic symptoms belong to the most frequent reasons to seek medical advice and are a burden both for the individual affected and the healthcare system. In Japan, the traditional herbal Kampo prescription rikkunshito has proven benefit for this indication. Methods: In a prospective, multicentre, non-interventional study (NIS), the effectiveness, safety, and tolerability of a two-week treatment with the registered rikkunshito extract product YamatoGast was assessed in German patients with an acute episode of dyspeptic symptoms of functional origin under real-world conditions. The primary endpoint was the responsiveness to treatment assessed by the overall treatment effect (OTE) score. Secondary endpoints were the change in severity of dyspeptic symptoms and the change in quality of life (QoL). Safety evaluation was based on reported adverse drug reactions, drug compliance, and ratings of tolerability by physicians and patients. Results: Sixty-six patients were enrolled (mean age 48.9 years, 74% females). The treatment was well tolerated and highly beneficial, as expressed by pronounced responder rates of 78.9% for the primary endpoint OTE. All secondary endpoints were also met. The severity of dyspeptic symptoms significantly improved by 62-77% compared to baseline, confirmed by a remarkable improvement of QoL. Significant symptom relief started from the third day of treatment onwards. Conclusion: In this non-interventional study, two-week treatment with YamatoGast resulted in a significant improvement of dyspeptic symptoms and was associated with high patient response and satisfaction. YamatoGast was confirmed as a safe and clinically relevant therapeutic option for patients suffering upper gastrointestinal complaints in routine practice. Competing Interests: HRH has received honoraria for consulting/speaking from Ominedo Pharmaceutical Industry Co Ltd., Japan. JT and KRD are employees of G. Pohl-Boskamp GmbH & Co KG. The other authors declare no conflict of interest. (Thieme. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|